MAL and renal carcinoma: We demonstrated here that high-MAL gene expression seems to confer survival advantages for patients with melanoma, lung adenocarcinoma, pancreatic adenocarcinoma, renal cancer, or colorectal adenocarcinoma (Figure 3A).